All In Biotech

NDA 019963 · Valeant Pharms North

Renova

Tretinoin · Topical

Discontinued

Last checked: Nov 20, 2026Latest source record: Jan 8, 2013 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1995

Dec 29, 1995

Approved uses

2

Original approval plus efficacy supplements

Registered trials

375

82 Phase 3, 25 recruiting

FAERS reports

6,666

4,154 serious, 856 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Therapeutic areas: Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 1, 2000 Supplement 5 · Efficacy LetterLabel
  • Dec 29, 1995 Original approval · Type 3 - New Dosage Form
1 products under this application
  • RENOVA · TRETINOIN 0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · CREAM, TOPICAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Tretinoin" as an intervention, any sponsor and status, largest first.

All 375 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use885
  • drug ineffective747
  • pain499
  • product use in unapproved indication483
  • vomiting452
  • paraesthesia376
  • abdominal pain upper368
  • rash367
  • nausea353
  • diarrhoea350
  • headache339
  • maternal exposure during pregnancy339

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200438
200533
200628
200740
2008115
200976
201080
201195
2012160
2013106
2014150
2015246
2016364
2017358
2018473
2019364
2020383
2021430
2022510
2023569
2024676
2025810
2026562

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 423 on PubMed

Sponsor: Valeant Pharms North

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.